Infinity Pharmaceuticals, Inc.
INFI
INFI was delisted on the 13th of September, 2023.
63 hedge funds and large institutions have $36.6M invested in Infinity Pharmaceuticals, Inc. in 2017 Q3 according to their latest regulatory filings, with 8 funds opening new positions, 15 increasing their positions, 26 reducing their positions, and 18 closing their positions.
15% less funds holding
Funds holding: 74 → 63 (-11)
32% less capital invested
Capital invested by funds: $53.7M → $36.6M (-$17.1M)
42% less repeat investments, than reductions
Existing positions increased: 15 | Existing positions reduced: 26
56% less first-time investments, than exits
New positions opened: 8 | Existing positions closed: 18
86% less call options, than puts
Call options by funds: $9K | Put options by funds: $64K
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
PIM
Platinum Investment Management
Sydney Australia 2000,
Australia
|
+$747K |
| 2 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
+$654K |
| 3 |
Renaissance Technologies
New York
|
+$547K |
| 4 |
Wellington Management Group
Boston,
Massachusetts
|
+$375K |
| 5 |
BCM
Bridgeway Capital Management
Houston,
Texas
|
+$310K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Vanguard Group
Malvern,
Pennsylvania
|
-$2.83M |
| 2 |
PA
Pinnacle Associates
New York
|
-$1.53M |
| 3 |
O
OrbiMed
New York
|
-$1.3M |
| 4 |
FCMI
Foresite Capital Management III
Larkspur,
California
|
-$1.16M |
| 5 |
Connor, Clark & Lunn Investment Management (CC&L)
Vancouver,
British Columbia, Canada
|
-$983K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
LTFS
76
Ladenburg Thalmann Financial Services
Miami,
Florida
| – | -$1.83K | -1,475 | -98% |
|
77
Manulife (Manufacturers Life Insurance)
Canada,
Ontario, Canada
| – | -$2K | -1,387 | Closed |
|
|
LJHT
78
Laurie J. Hall Trustee
| – | -$738 | -470 | Closed |
|
|
AFNAS
79
American Financial Network Advisory Services
Calabasas,
California
| – | +$159 | +128 | New |
|
INFI Hedge Fund Activity: Q3 2017 in Review
63 of the 4,012 institutional investors tracked by Wall St. Rank reported a position in Infinity Pharmaceuticals, Inc. (INFI) for Q3 2017, worth a combined $36.6M — down 32% from $53.7M a quarter earlier.
Sellers outnumbered buyers: 18 funds closed out of INFI and 8 opened new positions — a net loss of 10 holders — while 26 trimmed existing stakes and 15 added.
The largest buyer was Platinum Investment Management, adding an estimated $747K. The largest seller was Vanguard Group, cutting an estimated $2.83M.
- 63 institutional investors held Infinity Pharmaceuticals, Inc. (INFI) as of Q3 2017, down from 74 in Q2 2017.
- Funds reported $36.6M of Infinity Pharmaceuticals, Inc. stock for Q3 2017, down 32% quarter-over-quarter.
- 8 funds opened new Infinity Pharmaceuticals, Inc. positions in Q3 2017 and 18 closed out, a net change of -10 holders.
- The largest Infinity Pharmaceuticals, Inc. buyer in Q3 2017 was Platinum Investment Management, an estimated $747K added.
- The largest Infinity Pharmaceuticals, Inc. seller in Q3 2017 was Vanguard Group, an estimated $2.83M sold.
Based on aggregated 13F filings for Q3 2017.